LIXTE Biotechnology Provides Update On Recent Activities And Developments; Collaboration With NKI And Funding Support For New Colorectal Cancer Clinical Trial By Major Pharma Co; Preclinical Data Published In Journal EMBO Reports Shows LB-100 As...
LIXTE Biotechnology Provides Update On Recent Activities And Developments; Collaboration With NKI And Funding Support For New Colorectal Cancer Clinical Trial By Major Pharma Co; Preclinical Data Published In Journal EMBO Reports Shows LB-100 As...
LIXTE Biotechnology Provides Update On Recent Activities And Developments; Collaboration With NKI And Funding Support For New Colorectal Cancer Clinical Trial By Major Pharma Co; Preclinical Data Published In Journal EMBO Reports Shows LB-100 As Potentially Enhancing The Benefit Of Immunotherapy
LIXTE Biotechnology关于最新活动和进展的更新；与NKI的合作以及大型药品公司对新结直肠癌临床试验的资助支持；发表在EMBO Reports期刊上的临床前数据显示Lb-100有可能增强免疫治疗的效果。
-Collaboration with NKI and Funding Support for New Colorectal Cancer Clinical Trial by Major Pharma Company-
与NKI的合作以及大型药品公司对新结直肠癌临床试验的资助支持。
-Distinguished Oncologist Jan Schellens Joins LIXTE as Chief Medical Officer-
知名肿瘤学家Jan Schellens加入LIXTE担任首席医务官。
-Preclinical Data Published in Journal EMBO Reports Shows LB-100 as Potentially Enhancing the Benefit of Immunotherapy-
发表在EMBO Reports期刊上的临床前数据显示Lb-100有可能增强免疫治疗的效果。
-LIXTE to Present at Two Upcoming Investor Conferences-
LIXTE将在两个即将举行的投资者会议上发表演讲。
PASADENA, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ:LIXT), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company's recent activities.
2024年8月19日加利福尼亚州帕萨迪纳（GLOBE NEWSWIRE）—LIXTE Biotechnology Holdings, Inc.（“LIXTE”或“公司”）（纳斯达克代码：LIXT）是一家临床阶段的药品公司，开发一类新型的癌症治疗，以增强化疗和免疫治疗的效果，今天对公司最近的活动进行了更新。
"We are encouraged by the growing interest shown by major pharmaceutical companies in our proprietary compound, LB-100, as demonstrated by their support in clinical trial collaborations," said Bas van der Baan, LIXTE's President and Chief Executive Officer.
“我们对大型药品公司对我们的专有化合物Lb-100表现出的日益浓厚兴趣感到鼓舞，这一点得到了他们在临床试验合作中的支持，”LIXTE的总裁兼首席执行官Bas van der Baan说道。
